Cure My Disease

Don't miss your cure!

 Log in / Sign up

Computer alert aims to boost cholesterol treatment in heart patients

NCT ID NCT05088759

Disease control Sponsor: Brigham and Women's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an electronic alert in the medical record can help doctors prescribe better cholesterol-lowering medications for heart disease patients with high LDL. About 400 patients from a single hospital will be randomly assigned to have their doctor receive the alert or not. The goal is to see if the alert leads to more appropriate prescriptions and lower LDL levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
electronic alert-based decision support system
What this could lead to
If successful, this alert system could help more heart disease patients get the right cholesterol medication, potentially reducing their risk of future heart attacks or strokes.
What could go wrong
This is a small, single-center quality improvement study, not a large clinical trial. The alert may not change prescribing habits significantly, and results may not apply to other hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2021

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * patients ≥ 18 years old AND * admitted to the BWH Cardiovascular Medicine Service with a diagnosis (primary or secondary), medical history entry, or problem list entry of ASCVD (acute coronary syndromes, a history of MI, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease) AND * most recent (within 1 year) or current LDL-C value greater than 80 mg/dL AND * on a statin but not on ezetimibe and/or PCSK9 inhibitor will be potentially eligible for randomization Exclusion: -already receiving PCSK9 inhibitor therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASCVD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atherosclerotic cardiovascular disease hyperlipidemia hyperlipoproteinemia type V

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ASCVD Hyperlipemia, mixed

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.